Home › The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia
 

Keywords :   


The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia

2013-02-04 07:00:00| drugdiscoveryonline News Articles

The Medicines Company and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that they have formed an exclusive global alliance for the development and commercialization of Alnylam’s ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia

Tags: the of form company

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Forecast Discussion Number 18
03.07Hurricane Beryl Wind Speed Probabilities Number 18
03.07Hurricane Beryl Public Advisory Number 18
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Hurricane Beryl Forecast Advisory Number 18
03.07Hurricane Beryl Graphics
03.07Atlantic Tropical Weather Outlook
More »